Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MBX Biosciences, Inc.MBX · Entity 4247 | Chief Medical Officer | August 04, 2026 | August 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MBX Biosciences, Inc.
Report date August 04, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,399 |
Reported balance
After 2026-08-04 transaction · row 1
1 source rowRow 1 · 2026-08-04 · Sale · Disposed 370 · Balance 14,399 F1: The sales reported on this Form 4 represent shares of common stock sold by the Reporting Person to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement between the Reporting Person and the Company. F2: The price reported in Column 4 is a weighted average price. These shares were sold on an aggregate basis for all Company participants, at prices ranging from $65.21 to $66.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 represent shares of common stock sold by the Reporting Person to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement between the Reporting Person and the Company.
F2: The price reported in Column 4 is a weighted average price. These shares were sold on an aggregate basis for all Company participants, at prices ranging from $65.21 to $66.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 04, 2026 Filed Aug 5, 2026 20:57 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | SaleCommon Stock | 370 | $65.77 | $24,334.90 |
DisclosureSEC source: 0001193125-26-335373 · ownership.xml · nonDerivative · entry 1 Azoulay Salomon · CIK 0002030246 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,399 F1 · shares: The sales reported on this Form 4 represent shares of common stock sold by the Reporting Person to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement between the Reporting Person and the Company. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold on an aggregate basis for all Company participants, at prices ranging from $65.21 to $66.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 08, 2026 Filed May 11, 2026 20:01 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | Exercise / conversionStock option (right to buy) · Derivative | 15,003 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-216704 · ownership.xml · derivative · entry 6 Azoulay Salomon · CIK 0002030246 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,008 Underlying: Common Stock · 15,003 shares Expires 2034-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares underlying this option vested and became exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 08, 2026 Filed May 11, 2026 20:01 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | Exercise / conversionStock option (right to buy) · Derivative | 55,000 | $0.00 Strike: $10.46 | $0.00 |
DisclosureSEC source: 0001193125-26-216704 · ownership.xml · derivative · entry 5 Azoulay Salomon · CIK 0002030246 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,540 Underlying: Common Stock · 55,000 shares Expires 2034-08-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares underlying this option vested and became exercisable on June 24, 2025, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 08, 2026 Filed May 11, 2026 20:01 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | SaleCommon Stock | 15,003 | $38.30 | $574,614.90 |
DisclosureSEC source: 0001193125-26-216704 · ownership.xml · nonDerivative · entry 4 Azoulay Salomon · CIK 0002030246 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,769 F1 · date: The sales reported on this Form 4 represent the exercise and sale of common stock options by the reporting person pursuant to an approved Rule 10b5-1 trading plan adopted on January 27, 2026. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.00 to $41.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 08, 2026 Filed May 11, 2026 20:01 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | Exercise / conversionCommon Stock | 15,003 | $16.00 | $240,048.00 |
DisclosureSEC source: 0001193125-26-216704 · ownership.xml · nonDerivative · entry 3 Azoulay Salomon · CIK 0002030246 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,772 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: The sales reported on this Form 4 represent the exercise and sale of common stock options by the reporting person pursuant to an approved Rule 10b5-1 trading plan adopted on January 27, 2026. Read SEC document |
| May 08, 2026 Filed May 11, 2026 20:01 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | SaleCommon Stock | 55,000 | $38.38 | $2,110,900.00 |
DisclosureSEC source: 0001193125-26-216704 · ownership.xml · nonDerivative · entry 2 Azoulay Salomon · CIK 0002030246 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,769 F1 · date: The sales reported on this Form 4 represent the exercise and sale of common stock options by the reporting person pursuant to an approved Rule 10b5-1 trading plan adopted on January 27, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.00 to $41.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 08, 2026 Filed May 11, 2026 20:01 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | Exercise / conversionCommon Stock | 55,000 | $10.46 | $575,300.00 |
DisclosureSEC source: 0001193125-26-216704 · ownership.xml · nonDerivative · entry 1 Azoulay Salomon · CIK 0002030246 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: The sales reported on this Form 4 represent the exercise and sale of common stock options by the reporting person pursuant to an approved Rule 10b5-1 trading plan adopted on January 27, 2026. Read SEC document |
| May 06, 2026 Filed May 8, 2026 20:02 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | SaleCommon Stock | 231 | $29.54 | $6,823.74 |
DisclosureSEC source: 0001193125-26-214582 · ownership.xml · nonDerivative · entry 1 Azoulay Salomon · CIK 0002030246 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,769 F1 · shares: The sales reported on this Form 4 represent shares of common stock sold by the Reporting Person to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement between the Reporting Person and the Company. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold on an aggregate basis for all Company participants, at prices ranging from $29.23 to $29.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:16 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | GrantStock option (right to buy) · Derivative | 70,000 | $0.00 Strike: $39.07 | $0.00 |
DisclosureSEC source: 0001193125-26-035587 · ownership.xml · derivative · entry 2 Azoulay Salomon · CIK 0002030246 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-02-02 F2 · derivative.exercise_date: The shares underlying this option vest and become exercisable in forty eight (48) equal monthly installments, beginning on March 2, 2026, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:16 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-035587 · ownership.xml · nonDerivative · entry 1 Azoulay Salomon · CIK 0002030246 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs will vest over a four (4) year period in equal quarterly installments, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:17 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $10.49 | $0.00 |
DisclosureSEC source: 0000950170-25-014499 · ownership.xml · derivative · entry 1 Azoulay Salomon · CIK 0002030246 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2035-02-03 F1 · derivative.exercise_date: 25% of the shares underlying this option vest and become exercisable on February 3, 2026, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 21:11 UTC | MBX Biosciences, Inc. MBX · Entity 4247 | GrantStock Option (Right to Buy) · Derivative | 45,011 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000950170-24-106457 · ownership.xml · derivative · entry 1 Azoulay Salomon · CIK 0002030246 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,011 Underlying: Common Stock · 45,011 shares Expires 2034-09-11 F1 · derivative.exercise_date: 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.